If January is a sign of things to come for 2021, traders and investors are going to make a lot of money this year. 4 penny stocks on the move to start 2021 are Cerebain Biotech (OTCMKTS: CBBT), TPT Global Tech (OTCMKTS: TPTW), Bionano Genomics (NASDAQ: BNGO), and Sorrento Therapeutics (NASDAQ: SRNE).
HOW TO TRADE PENNY STOCKS
First up, it’s important to understand that trading penny stocks is not the same as trading blue chips. As we have stressed repeatedly to our subscribers, the key to trading penny stocks is finding momentum BEFORE it happens and then be patient.
We got our subscribers in early on TSNP, which you can read our latest here, and ENZC, which you can read about here. It’s also best to own a portfolio of quality penny stocks. For some that can be as many as 10 to 20 or more penny stocks.
Now, when we say that we find momentum BEFORE it happens, we are investors looking to position our subscribers BEFORE the move happens. This is where the big money is made and why so many of our subscribers are sitting on gains of over 7750% in ENZC and over 18,650% in TSNP.
We always alert our subscribers first before we publish for our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here. We alert our subscribers with our best ideas before our regular readers.
Now we know many prefer to day trade, but we are not day traders here at Insider Financial. It doesn’t suit our personality and we don’t like the intraday moves markets make. We have found we made more money being patient and ignoring the day to day noise of the markets.
If you want to day trade, Insider Financial is not the place for you. When it comes to day trading, and if that’s what you are after, we recommend the folks at True Trading Group, which you can check out their live streams here.
OTC PENNY STOCKS VS NASDAQ PENNY STOCKS
The fact is that there is always a bull market somewhere. That’s why it’s important for penny stock investors to trade both OTC and NASDAQ/NYSE penny stocks. There are always opportunities if you give yourself the flexibility to trade all markets.
Last year, for the first half of 2020, it was much more profitable to trade NASDAQ penny stocks than OTC. That is where we and our subscribers were positioned. We captured the runs in SRNE, NIO, INO, IBIO, WKHS, and many others. Then once the summer came, many of the COVID runners had failed to find momentum. We then pivoted to OTC and caught the runs in TSNP, ENZC, MMEDF, and many others.
So far this year, it’s best to play both OTC and NASDAQ. With Bitcoin running, we are seeing crypto plays making huge moves. With Joe Biden coming into the White House and Democrats taking control of the Senate, we are seeing cannabis and green energy plays catching bids.
In this article, we take a look at 4 penny stock on the move CBBT, TPTW, BNGO, and SRNE to find out what’s behind the move and our outlook for each.
Penny Stock #1 CBBT
CBBT has been a monster runner for Insider Financial subscribers. We said back in October:
Cerebain Biotech (CBBT) has turned into a monster runner and a massive win for our subscribers that got our alert in September. Most of our subscribers have averaged in around $.002 and saw a huge run to $.012 this month. This also makes shares of CBBT awfully cheap under a penny…there’s still a lot more room for CBBT to run before the New Year.
After closing the week at $.12 a share, subscribers that stayed in are sitting on potential gains of 5899%!
The reason for the big run is the acquisition of PKG Inc. by Cerebain Biotech. PKG was doing $21 million in revenues before COVID-19 hit. For 2020, PKG is estimated to post around $14 million in revenues and then return to pre-COVID levels in 2021.
Markets are now just waiting for the acquisition to close (hopefully by the end of January) and for CBBT to bring its filings up to date. Our only concern is that the closing of the acquisition seems to be taking longer than expected. After all, another big runner for us in 2020 was TSNP and TSNP announced the completion of its merger with HUMBL in less than a month from the time it was announced. A failure by CBBT to close the acquisition with PKG would crush its share price. Any reader or subscriber sitting on big gains would be wise to take SOME money off the table.
CBBT has a current market cap of $85 million.
Penny Stock #2 TPTW
TPTW is another monster runner from last summer on the back of the COVID-19 pandemic, which we last covered in October.
TPTW is running again as the company drops a steady stream of PRs about its “QuikPass” Check and Verify and Vaccination monitoring platform for Corporations, Government Organizations, Schools, Airlines, Hospitals, Sports Venues, Restaurants, Hotels, and Nightclubs.
QuikPass can check and verify that an individual has been tested for Covid 19 or Vaccinated providing proof individuals are virus-free and able to gain access to venues with the idea that everyone inside that venue would be Covid free.
The “QuikPass” “Check and Verify” platform works with third-party testing labs and organizations that participate in the “QuikPass” Network and will be offered FREE to US domestic and international business commerce and government organizations around the world.
With a current market cap of just $46 million and a steady stream of PRs, we expect TPTW to hit new highs sooner rather than later.
Penny Stock #3 BNGO
We recommended BNGO to our subscribers to start the New Year. After making new highs on Friday, we still see more room for BNGO to run, especially if Cathie Wood’s ARK ETFs add BNGO to its portfolio. After all, they have PACB in their portfolio and PacBio’s HiFi chemistry was only able to detect 72% of the large SVs (structural variants) detected by Saphyr.
The news regarding Saphyr has been very, very good. Featured in day two of Bionano’s five-day Cytogenomics Symposium, presentations by scientists and clinicians suggested that the platform is cost-effective, provides actionable information faster, in a single assay. It was reported that Saphyr is capable of identifying actionable variants in hematological malignancies detected by several cytogenomic methods combined, as well as additional variants missed by traditional methods.
According to presentations on Day three, the preliminary readout on Saphyr validation study for brain cancer presents a path to solid tumor laboratory-developed test. It outperforms Oncoscan array for structural variation and copy number variation detection in solid tumors, as well as provides a comprehensive and clear picture of structural variation in solid tumors, which has not been possible to date with NGS or array.
Presentations on day four concluded that the Saphyr platform can measure large expansions of disease-causing genomic repeats, which may not be possible with other modern techniques. Genetic disease cases undiagnosed using existing methods were solved by optical genome mapping, including muscular dystrophy testing.
BNGO has a current market cap of $1.37 billion compared to $6.16 billion for PACB.
Penny Stock #4 SRNE
SRNE was a penny stock that we positioned our subscribers in around $4 before its run to almost $20 in just 2 months, which you can read here.
SRNE is running again after H.C. Wainwright gave the stock a $30 price target. Analyst Ram Selvaraju projects $321M in total for Sorrento’s investments in Celularity, a clinical-stage cell therapeutics company, and NantKwest (NASDAQ: NK), which recently climbed in value in response to impressive mid-stage trial data in advanced pancreatic cancer.
Once merged with GX Acquisition Corp. (NASDAQ: GXGX) to go public, the stake at Celularity will be worth $200M Ram estimates, adding another $121M for the investment in NantKwest based on its current share price.
The analyst also highlights Sorrento’s “burgeoning portfolio of assets spanning three distinct therapeutic areas (non-opioid pain management, oncology, and COVID-19).” Late December, Sorrento filed the Emergency Use Authorization (“EUA”) application for its COVI-STIX rapid diagnostic test for the detection of the SARS-CoV-2 virus.
SRNE can continue to climb as 31% of the float is short. Last summer’s big spike was a result of the shorts getting squeezed and we expect this time will be no different. $30 is a very realistic target when you consider the large short position and all the upcoming catalysts for SRNE.
These 4 penny stocks are hot right now. There are always opportunities in penny stocks and it’s our job to find the bull markets. Huge gains can be made in such a short amount of time.
For those that missed out on the recent run in these 4 penny stocks, our best advice is to be patient and throw bids in below the market. Buying dips and selling rips as swing trades remains the best strategy in these markets.
Remember, all it takes is one or two to become a CBBT, TPTW, BNGO, or SRNE and you’ve crushed the market indices for the year. Whoever said to avoid penny stocks has no clue what they’re doing.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.